MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at ...

Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...

Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning ladies and gentlemen and welcome to PDS Biotech’s Third Quarter 2024 Results and Clinical Strategy Update Conference Call. All ...

The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

Vibostolimab/Keytruda regimen did not improve overall survival compared to Tecentriq in extensive-stage SCLC patients. Median ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...